Adam Cartwright

Adam Cartwright is a Senior Scientist II at Monte Rosa Therapeutics since November 2022, with prior experience as a Senior Scientist at Evelo Biosciences from January 2020 to November 2022, where leadership of the In Vivo Pharmacology team was key in exploring SINTAX medicines for novel disease indications. Previously, Adam served as a Postdoctoral Research Fellow at Dana-Farber Cancer Institute from March 2015 to January 2020, earning the Cancer Research Institute Irvington Fellowship and conducting significant research on immunotherapy targets for melanoma. Academic achievements include a PhD in Immunology and an MSc in Molecular Medicine from Imperial College London, complemented by a B.Med.Sci in Biomedical Materials Science from the University of Birmingham, and extensive training from early educational experiences in biology, chemistry, and mathematics.